Last reviewed · How we verify
D-0120 in combination with Allopurinol — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
D-0120 in combination with Allopurinol (D-0120 in combination with Allopurinol) — InventisBio Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| D-0120 in combination with Allopurinol TARGET | D-0120 in combination with Allopurinol | InventisBio Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- D-0120 in combination with Allopurinol CI watch — RSS
- D-0120 in combination with Allopurinol CI watch — Atom
- D-0120 in combination with Allopurinol CI watch — JSON
- D-0120 in combination with Allopurinol alone — RSS
Cite this brief
Drug Landscape (2026). D-0120 in combination with Allopurinol — Competitive Intelligence Brief. https://druglandscape.com/ci/d-0120-in-combination-with-allopurinol. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab